Based on this analysis, avapritinib has been used as a treatment option after disease progression during therapy with the standard FDA-approved TKIs for late-line GIST, especially for patients with documented KIT exon 17/18 and/or KIT exon 9 mutation, although it is not approved for this indication. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.